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SUMMARY
The cancer-ageing hypothesis suggests that the activation of some tumor suppressor mechanisms
beneficially prevent cancer but also untowardly promote mammalian ageing. Along these lines,
activation of tumor suppressor mechanisms that inhibit the cell cycle (e.g. p16INK4a and p53) in
response to DNA damage and other age-promoting stimuli have taken center stage in immune-ageing
research. Immune cells are intrinsically susceptible to transforming events due to V(D)J
recombination, a high rate of cellular turnover and requisite long-term self-renewal. Therefore, the
DNA damage response and cell cycle regulation play a clear role in maintaining homeostasis without
neoplastic progression. Here we will argue based on recent advances in our understanding of tumor
suppressor mechanisms in immune cells, however, that aspects of these same beneficial pathways
have the potential to induce intrinsic immune ageing.
INTRODUCTION
Aspects of mammalian ageing appear to result from the persistent activation of related tumor
suppressor mechanisms by diverse gerontogenic stimuli. Such age-promoting signals probably
include environmental mutagens (e.g. UV radiation), as well as intrinsic replicative and
metabolic stresses (e.g. reactive oxygen species (ROS)). DNA damage, either alone, or
downstream of some of these stresses is associated both with ageing and the activation of tumor
suppressor mechanisms (Figure 1); however, the exact stimuli that promote their activation in
ageing are unknown.
Immune cells possess unique characteristics that make them susceptible to malignant
transformation. Both T and B lymphocytes undergo dramatic proliferation and V(D)J
recombination to obtain their massive antigen receptor diversity during their development.
Upon pathogen encounter, they engage in clonal expansion and B lymphocytes also go through
somatic hypermutation to achieve higher BCR affinity. Additionally, memory lymphocytes
undergo self-renewal, and maintain impressive replicative capacity in response to antigenic
challenges, even after decades without such stimulation. As a result, the DNA damage response
and other tumor suppressor mechanisms appear to be finely regulated to allow for this unusual
proliferative behavior.
Here, we will argue that activation of tumor suppressor pathways in response to age-promoting
(“gerontogenic”) stimuli promote immune ageing by inducing a proliferative compromise,
perhaps even cellular senescence, or an increased propensity to undergo apoptosis; and we
Corresponding Author: Norman E. Sharpless, Phone: (919) 966-1185, Fax: (919) 966-8212, E-mail: nes@med.unc.edu.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers
we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting
proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could
affect the content, and all legal disclaimers that apply to the journal pertain.
NIH Public Access
Author Manuscript
Curr Opin Immunol. Author manuscript; available in PMC 2010 August 1.
Published in final edited form as:













suggest these cell-intrinsic alterations contribute to ageing of the immune system. It is also
important to note that cell extrinsic factors, such as degradation of immunologic “niches” and
alterations of the hormonal milieu undoubtedly play an important role in mammalian immune
ageing. For example, thymic involution contributes to reduced thymic output with ageing
(reviewed in [1]) and hematopoietic stem cell (HSC) ageing is partially determined by the bone
marrow microenvironment [2]. Although such extrinsic mechanisms are of doubtless
physiologic importance in ageing, in this review, we will focus on cell-intrinsic ageing of the
immune system that results from tumor suppressor activation.
The induction of age-promoting tumor suppressor mechanisms
A common feature of several “gerontogens” is the induction of DNA damage with subsequent
initiation of DNA Damage Response (DDR) pathways. Alteration in DNA metabolism is
associated with features of premature ageing in a few human genetic diseases (e.g. Werner
syndrome [3]), as well as several mouse models (reviewed in [4]). These data have advanced
the hypothesis that DNA damage and/or the cellular responses activated as part of the DDR
promote ageing. One of the most important responders of the DDR is the p53 tumor suppressor,
which is activated by a series of kinases that sense several forms of DNA damage (Figure 1).
Additionally, p53 can also be stabilized by “mitogenic stress” through induction of the Arf
tumor suppressor gene, and this is thought to occur largely independent of DNA damage [5].
Arf is transcribed in an ‘Alternate Reading Frame’ with another tumor suppressor gene,
p16INK4a, that is also thought to regulate ageing (reviewed in [6]). Importantly, the p53
transcription factor engages a diverse set of cellular pathways which can lead to a variety of
outcomes including enhanced DNA repair, a transient cell cycle arrest, a permanent growth
arrest (i.e. senescence), or apoptosis depending on the quality, intensity and persistence of the
damaging signal (Figure 2). Given these diverse possible outcomes of p53 expression, it is
perhaps not surprising that p53 has been suggested to both accelerate and retard mammalian
ageing when activated in different contexts in murine systems [7–10••]
The induction of the p16INK4a tumor suppressor gene is less well-understood. Several diverse
stresses have been shown to increase p16INK4a expression, among them oxidative stress,
oncogene activation and telomere dysfunction (Figure 1). Expression of p16INK4a leads to
decreased activity of the CDK4/6 proliferative kinases with attendant RB hypophosphorylation
and growth arrest in some, but certainly not all, proliferating cell types [11,12]. Under some
circumstances, p16INK4a activation and persistent RB hypophosphorylation can induce cellular
senescence [6]. It is worth noting that by “cellular senescence”, we refer to a specialized,
permanent form of growth arrest originally described by Hayflick and colleagues. This should
not be confused with “immunosenescence” and related terms used generically to describe
cellular hypoproliferation noted in the ageing immune system. Cellular (‘Hayflickian’)
senescence represents a precise cell biological phenotype where cells are irreversibly arrested
in G1 phase, but remain metabolically active, and viable indefinitely [13]. In contrast,
“replicative senescence” of lymphocytes has been used to refer to limited proliferation upon
mitogen or antigen stimulation seen in cells from aged organisms [14]. Importantly, expression
of p16INK4a has been closely linked to the Hayflickian senescence of cultured human cells,
whereas the importance of p16INK4a for “immunosenescence” is an area of ongoing
investigation. For the purposes of clarity, in this review, we will reserve the term “senescence”
for the more precisely defined, permanent growth arrest described by Hayflick.
Does telomere dysfunction cause immune ageing?
Telomere dysfunction appears to increase in primates with physiological ageing [15], and has
been linked to p53 and p16INK4a activation. Telomeres are nucleoprotein structures that act to
protect chromosome ends from degradation. They are composed of numerous 5′ TTAGGG 3′
repeats (in vertebrates), a 3′ G-rich overhang and the protein complex named shelterin
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(reviewed in [16]). Telomeres shorten with each round of cell division due to the inability of
DNA polymerase to completely copy terminal linear DNA sequences. Telomere shortening is
thought to limit proliferative capacity, and therefore may serve as a barrier to turmorigenesis,
at least in the context of intact p53 function. Telomerase is a specialized RNA-protein complex
that synthesizes telomere repeats de novo and maintains telomere length during cell division.
Telomerase is expressed in germ cells but is absent in most human somatic tissues [5]. Critically
shortened telomeres cannot be bound by the shelterin complex and form uncapped telomere
ends, which are subsequently recognized as double strand breaks (DSBs) and cause initiation
of DDR.
Several lines of evidence have suggested that telomere dysfunction may contribute to human
ageing. Telomerase-deficient mice that have been serially backcrossed to harbor human-length
telomeres demonstrate regenerative failure in multiple organs due to a decline in stem cell
proliferative capacity and tissue repair ability [17], showing that telomere dysfunction can
induce aspects of the impaired tissue regeneration characteristic of human ageing. Likewise,
while humans with WRN deficieny exhibit a profound progeria, Wrn-deficient mice do not
appear progeroid except in the setting of shortened telomeres [18]. In the immune system,
telomerase is required to maintain HSC lifespan during serial transplantation [19] and to
prevent ageing-related abnormal B cell and myeloid hematopoiesis in mice [20,21••]. In
addition, human CD28 negative T cells, which have lost optimal telomerase activity,
accumulate in vivo with age and display impaired function [22], and the overexpression of
telomerase or activation of telomerase using small molecules partially rescues these defects
[22,23•]. Patients with dyskeratosis congenita (DKC) and other diseases that harbor genetic
defects in telomerase activity also display some features of premature ageing (reviewed in
[16]). In particular, some DKC patients exhibit immune ageing phenotypes, such as
lymphopenia and lymphocyte hypo-proliferation [24].
On the other hand, evidence has suggested that many aspects of ageing can occur in the absence
of telomere dysfunction, and it is not clear if telomeric signals usually contribute to human
ageing under physiological settings. For example, mean telomere length correlates poorly with
ageing [25,26], and telomere shortening is only weakly associated with most common human
age-associated diseases [27–29]. Secondly, while normal inbred mice demonstrate many
familiar aspects of mammalian ageing, this appears to be almost entirely telomere-independent,
as telomerase-deficient mice demonstrate only subtle abnormalities with regard to ageing
[17]. Moreover, as in Terc-deficient mice, phenotypes of telomerase deficiency in humans are
generally seen in patients who also inherit shortened telomeres from parents with telomerase
deficiency (termed ‘anticipation’) (reviewed in [16] ). Thirdly, other than perhaps cirrhosis,
classic ageing phenotypes such as atherosclerosis, type 2 diabetes mellitus, osteopenia, or
neurodegenerative disease have not yet been reported in human patients with telomerase
deficiency. That is, humans harboring sufficient telomere dysfunction to induce overt disease
such as aplastic anemia and pulmonary fibrosis do not exhibit a segmental progeria akin to that
seen in WRN patients. We believe these data for and against the role of telomere dysfunction
in human ageing, when taken in aggregate, suggest that telomere dysfunction likely contributes
to age-associated phenotypes in humans, but it still remains unclear as to whether telomere
dysfunction plays a major or minor role in these processes.
Complex roles in ageing for the p53 pathway
As mentioned, activation of p53 can induce a variety of responses including transient cell cycle
arrest (often accompanied with DNA repair), senescence or apoptosis. Correspondingly, recent
studies in mouse models have indicated that the effect of p53 activation on ageing is complex
(Figure 2). In some murine models, activation of p53 appears to generally accelerate ageing
[7,8]. With regard to immune function, deletion of p53 in mice increases the number and
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abrogates the age-related decline of HSC self-renewal capacity [30–32]. Likewise, increased
p53 dosage causes reduced repopulating capacity in HSCs [10••]. Deletion of p53 rescues the
ageing phenotype of stem cells in mice with dysfunctional telomeres, but fails to extend the
life span of these animals due to increased tumor susceptibility [33]. In contrast, inactivation
of p21CIP, a p53-target that induces cell cycle arrest, rescues proliferative defects of stem cells
in telomerase deficient mice and extends their longevity [34]. These data suggest a pro-ageing
role of the p53 pathway in certain settings.
In other systems, however, p53 activation has been shown to delay ageing. Mice harboring
extra copies of the p53 and Ink4a/Arf genes (super Ink4a/Arf/p53 mice) display an extended
longevity, decreased malignancy and enhanced protection from DNA damage [9••,35], while
mice have reduced gene dosage of MDM2 or an extra copy of either ARF or p53 do not exhibit
accelerated ageing (reviewed in [35]). Consistent with these data, inactivation of Arf in a
premature ageing mouse model (BubR1 insufficient) leads to exacerbated ageing phenotype,
while loss of p16INK4a rescues aspects of this progeria [36•]. Also of interest, p53-deficient
mice show accelerated ageing in the T cell compartment [37]. These data suggest Arf-p53
function can be anti-ageing, presumably by augmenting DNA repair and therefore preserving
genomic integrity.
These two seemingly contradicting roles of p53 in ageing may result from differences in the
quality or persistence of the stimuli that activate p53 expression. Some activating signals may
skew its response towards transient arrest and DNA repair, thereby restoring normal
homeostasis and acting as an anti-ageing checkpoint. Additionally, the persistence of the
stimuli that induces p53 may be important. Long-term p53 activation, as occurs with telomere
dysfunction, might promote senescence or cell death, whereas transient activation might
enhance genomic fidelity. In accord with these views, the progeroid p53 overexpresing mice
[8,10••] appear to have a greater and more persistent degree of p53 activation compared to the
super-p53 mice [9••,35] which do not show accelerated ageing. Correspondingly, loss of the
p53 target gene, p21CIP, which induces an important, transient cell cycle pause after DNA
damage compromises long-term HSC function during serial transplantation [38–40••], but
significantly enhances HSC function in the setting of persistent telomere dysfunction [34]. We
believe the murine data suggests that the effects of the pleiotropic p53 transcription factor with
regard to ageing depend on the nature and duration of the stresses that engage p53 in vivo.
p16INK4a-pRB pathway and senescence
The p16INK4a tumor suppressor is an important mediator of cellular senescence, and recent
work has suggested it may also play a role in human ageing [6] (Figure 3). Expression of
p16INK4a is induced upon T cell activation and has been shown to possibly cause hypo-
proliferation before cells reach permanent, possibly senescent growth arrest in vitro, in which
T cells cease responding to stimulation in culture [41]. These observations raise the critical
question as to whether p16INK4a can promote ageing by inducing hypoproliferation (e.g. in T
cells) without necessarily causing true ‘Hayflickian’ senescence in vivo.
The expression of p16INK4a has been shown to sharply increase with ageing in the majority of
human, baboon and rodent tissues tested to date [17]; and caloric restriction, which retards
ageing in rodents, attenuates age-induced increase in p16INK4a expression [42,43]. Recent
studies [44–47••] have demonstrated that increased p16INK4a expression in mice causes an age-
associated functional decline in HSCs, pancreatic islet cells, neural stem cells (NSC), and B
lymphocyte progenitors [47••]. Accordingly, p16INK4a deletion attenuates the age-related
decline in the repopulation potential of stem cells in these compartments [44–46] and partially
rescues premature ageing in skeletal muscle and fat tissues in a premature ageing mouse model
(BubR1 insufficient) [36•].
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Recent evidence has also linked p16INK4a expression to human ageing. For example, we have
recently shown that p16INK4a expression in human peripheral blood T cells increases sharply
with ageing and strongly correlates in independent samples with gerontogenic behaviors such
as smoking and physical inactivity [48•]. Moreover, findings from human association studies
have recently linked p16INK4a expression to several human age-related phenotypes. Single
nucleotide polymorphisms (SNPs) whose genotypes are associated with the risk of age-related
conditions, such as frailty, type 2 diabetes mellitus, stroke and myocardial infarction, have
been mapped by candidate approaches and genome-wide studies to within 120 kb of the human
INK4/ARF locus (reviewed in [17]). We have recently identified that the expression level of
p16INK4a and other INK4a/ARF transcripts in peripheral T-cells is strongly correlated with a
common, non-coding SNP ~100 kb away from p16 INK4a promoter [49]. Although the precise
mechanistic linkage between these 9p21 SNPs and human ageing are still unclear, these data
provocatively suggest an important link between p16INK4a expression and human ageing.
Precisely what aspect of mammalian ageing induces p16INK4a expression is unknown.
However, p16INK4a activation has been shown to be regulated at transcriptional and
posttranscriptional levels (Figure 3). MAPK signaling via ERK and p38MAPK has been
suggested to induce p16INK4a expression in response to oncogenic activation or stress stimuli.
Expression of p16INK4a can be either transcriptionally activated (e.g. Ets family ) or inhibited
(e.g. Id proteins) by a number of pathways (reviewed in [6]). Although the majority of research
has focused on transcriptional control, recent studies have suggested that p16INK4a can be
regulated post-transcriptionally through interaction with microRNAs [50]. A particular link
has been suggested between p16INK4a expression and PcG function. The PcG proteins BMI-1
[51–53], EZH2 [54–56•] and CBX7 [57] have been shown to act as epigenetic repressors of
p16INK4a expression. Consistent with these data, Bmi-1 deficient mice display accelerated HSC
attrition [53,58], reduced self-renewal of neural stem cells (NSC) [52], postnatal growth
retardation and neurological defects [59], and diminished β-cell mass and phenotypes of T2DM
[60•]. Importantly, the defects in HSC and NSC observed in Bmi-1 deficient animals are
partially reversed by deletion of Ink4a/Arf [51,52,61,62]. Recent data has further suggested
that an age-induced loss of PcG function may contribute to the increased expression of
p16INK4a seen with ageing. For example, loss of Ezh2 and Bmi-1 binding to the INK4a/ARF
locus has been reported with prolonged fibroblast culture with attendant increased expression
of the locus in senescent cells [55]. Most recently, loss of EZH2 expression has been reported
in pancreatic β-cells in vivo with ageing in humans and mice [56•]. Furthermore, specific
somatic deletion of Ezh2 in this tissue causes Ink4a/Arf overexpression, a relative failure of
insulin secretion and hyperglycemia; which can be rescued by Ink4a/Arf deficiency. These
results suggest the possibility that a loss of PcG repression with ageing contributes to the
observed increase in expression of p16INK4a noted in several human tissues.
With regard to immune ageing, besides its role in limiting HSC and B cell progenitor
proliferation potential with ageing, p16INK4a has been shown to play an important role in
immune cell development [63] and myeloid cell senescence [64]. Overexpression of
p16INK4a in T cells arrests thymocyte development at the DN stage presumably through
induction of hypo-proliferation during thymocyte differentiation [63]. Consistent with this
result, p16INK4a mediates peripheral T cell replicative senescence/hypo-proliferation [41,65]
and p16INK4a deficient mice have increased thymocyte and peripheral T cell number [66,67].
However, it is not known whether p16INK4a plays an intrinsic role in the ageing-related
functional declines observed in terminally differentiated lymphocytes. It is recognized that
immunological microenvironments play an essential role in the age-related changes
documented for lymphocyte development and function [1]. However, current mouse models
do not allow us to determine whether p16INK4a functions intrinsically or extrinsically in naive
and memory lymphocyte ageing. Long-term bone marrow transplantation experiments or
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future mouse models with lineage-specific deletion of p16INK4a are needed to address these
questions.
CONCLUSIONS
In summary, the activation of tumor suppressor mechanisms in immune cells appears to provide
an important defense against malignant transformation caused by DNA damages and other
stimuli during their development, homeostatic replication and activation. Activation of these
tumor suppressor mechanisms can lead to both pro- and anti-ageing effects in immune cells.
For example, transient p53 activation likely induces a beneficial cell cycle pause and
opportunity for DNA repair that affords a resistance to certain age-promoting stimuli. In
contrast, gerontogenic stresses such as telomere dysfunction and other forms of persistent DNA
damage appear to activate apoptosis and senescence via p53 and p16INK4a induction, which
appears to be pro-ageing in some settings.
Major challenges going forward will be to understand immune ageing on a tissue, rather than
cellular, level: that is, how these cell-intrinsic activities influence the behavior of the affected
cells and interact with cell-extrinsic changes to produce organismic immune ageing. For
example, p16INK4a expression has been noted in several subsets of lymphocytes with ageing,
but we think it is unlikely that all types of proliferation in these diverse subsets of lymphocytes
are affected by p16INK4a expression. More likely, we think that certain lymphocyte
proliferative events will be specifically retarded by an age-induced increase in p16INK4a
expression, whereas the replicative capacity of other lymphocyte subsets may not be adversely
compromised, or perhaps even increased, in the setting of p16INK4a induction. Likewise, an
age-induced decline in the replicative capacity of certain cell types (e.g. T regulatory cells),
may extrinsically lead to increased proliferation in other immune subsets. Sorting out the
physiology of immune ageing will require carefully designed murine studies using conditional
alleles, as well as more longitudinal studies of human immune ageing.
Another important issue is whether the pro- or anti-ageing effects of p53 predominate in
humans. In this regard, it is important to note that conclusions about p53 regulation from mice
may be of limited applicability to humans. There are important differences in ARF regulation
and telomere biology between humans and rodents that may be of relevance to the role of p53
in ageing. As mentioned, telomere length is shorter and telomerase activity is more tightly
regulated in humans compared to rodents, and therefore telomere dysfunction may be an
important activator of p53 in human, but not rodent, ageing. Likewise, while Arf expression
increases markedly with ageing in most rodent tissues [42,68] with a correlative increase in
the expression of p53 target genes [42,43], expression of ARF has not been observed to increase
with age in any human tissue tested to date, including T lymphocytes [48•] and kidney [69].
Likewise, human ARF does not increase with the onset of cellular senescence, nor is human
ARF induced by ectopic RAS expression in vitro; whereas murine Arf markedly increases in
expression during these settings (reviewed in [6]). It is tempting to speculate that species
differences in the PcG repression of the INK4a/ARF locus [54,55] account for these differences
in ARF regulation with ageing, although other explanations are also possible. Nonetheless,
these major differences between mouse and man with regard to telomere and ARF biology
suggest that care must be taken in drawing conclusions about the role of p53 in human ageing
based on murine studies.
In summary, we believe the activation of tumor suppressor genes and cell cycle inhibitors
influences immune ageing, and likely contributes to a cell-autonomous decline in cellular
replicative capacity in specific immune cell subsets (e.g. B-cell progenitors [47••]). We believe
future studies of immune ageing will allow for the identification of reliable molecular markers
of molecular ageing to assess the progression of immune ageing and possibly forecast the onset
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of certain age-associated diseases. Moreover, an enhanced understanding of the pro- and anti-
ageing roles of tumor suppressor activation may provide therapeutic opportunity. Although we
remain concerned that efforts to attenuate tumor suppressor responses risk enhanced neoplasia,
we anticipate that a more sophisticated understanding of cellular ageing will permit the design
of rational anti-ageing therapeutics to retard the pace of immune ageing.
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Figure 1. Tumor suppressor mechanisms and their role in cancer and ageing
In response to exogenous gerontogens and endogenous damage signals, the tumor suppressors
p53 and p16INK4a are activated to prevent cancer but can also untowardly promote mammalian
ageing through inducing cell growth arrest, senescence and apoptosis. Activation of p53,
however, can also engage a transient cell cycle arrest and DNA repair that may retard ageing.
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Figure 2. Activation of p53 pathway in immune ageing
Many age-promoting stimuli can lead to activation of p53 pathway through ATM/ATR-
dependent DDR pathway or a DNA damage independent ARF-HDM2 pathway. ATM and/or
ATR, together with CHK1 and/or CHK2, facilitate activation of p53 in response to DNA
damage. In addition, p53 activation can also be induced by ARF in response to oncogene
activation, PcG loss or other unknown mechanisms. ARF inhibits HDM2 (MDM2 in mice)
and stabilizes p53 expression. Among a suite of p53 targets, p21CIP is activated and causes a
transient cell cycle arrest. Apoptosis and senescence can also be triggered through other p53
downstream pathways. Both apoptosis and cellular senescence lead to ageing at the organism
level, while transient arrest and DNA repair could restore normal homeostasis and delay ageing.
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Figure 3. Regulation of p16INK4a and its role in immune ageing
Senescence-inducing signals (e.g. mitogen stimuli and other unknown ageing-promoting
stimuli) activate the p16INK4a pathway by upregulating p16INK4a expression, which can be
achieved through a variety of mechanisms, including epigenetic, transcriptional, and
posttranscriptional regulation. It is not clear whether different stress-related signals employ
one or more specific mechanisms to regulate p16INK4a expression. However, once activated,
p16INK4a inhibits the proliferative kinases CDK4/6, leading to immune ageing through
induction of hypo-proliferation, and perhaps cellular senescence.
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